Skip to main content

Table 8 TEAEs by age group in the dose-optimization phase while receiving LDX with an incidence of ≥10% in the dose-optimization and/or crossover phase

From: Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day

AE-Preferred Term

Dose-Optimization Phase

 

6 to 9 year olds

10 to 12 year olds

 

(n = 48)

(n = 81)

 

n (%)

n (%)

Any AE

43 (89.6)

67 (82.7)

Abdominal pain upper

8 (16.7)

12 (14.8)

Affect lability

7 (14.6)

6 (7.4)

Anorexia

5 (10.4)

2 (2.5)

Decreased appetite

23 (47.9)

38 (46.9)

Headache

9 (18.8)

13 (16.0)

Insomnia

17 (35.4)

18 (22.2)

Irritability

7 (14.6)

14 (17.3)

Back to article page

Child and Adolescent Psychiatry and Mental Health

ISSN: 1753-2000